Altre lingue Scilex Holding Company

Azioni

SCLX

US80880W1062

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 07/05/2024			Variaz. 5gg	Var. 1 gen.
0,9173 ^USD	+5,98%		+7,51%	-55,03%

16/04	Scilex pubblica i risultati preliminari delle vendite del Q1 di ZTlido	MT
20/03	Scilex chiede l'approvazione della FDA per aggiungere indicazioni sul dosaggio all'etichetta del farmaco per il trattamento della gotta	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Scilex Holding Company Announces $15 Million Registered Direct Offering	24/04
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results for Gross and Net Sales for ZTlido for the First Quarter 2024	17/04
Scilex Issues Preliminary Q1 Sales Results for ZTlido	16/04
Scilex Holding Company Provides Certain Preliminary Unaudited Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024; Implements Planned 2024 Commercial Ramp for Additional Opioid Sparing Product and Reduction of R&D and Other Administrative Expenses	16/04
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group	10/04
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido® and ELYXYB® for Commercially Insured Patients and the addition of ELYXYB® to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool	09/04
Scilex : Submission of Matters to a Vote of Security Holders - Form 8-K	05/04
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend	27/03
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients	21/03
Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label	20/03
Scilex Settles Patent Dispute With Takeda Pharmaceutical Over Gloperba	20/03
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba® Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed	20/03
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba®? Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed	20/03
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex’s Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchicine Product, Gloperba®	20/03
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation	19/03
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada	18/03
Scilex Holding Company Provides Responses to Product Composition Questions Related to Its ELYXYB® Patent in Canada	18/03
Scilex Holding Announces Issuance of Halal Certification for its ZTlido® product by Circle H International, Inc.	15/03
Scilex Settles Claims in Case Against Virpax for $6 Million, 6% Royalties From Three Drugs	15/03
Scilex Holding Company’s Wholly Owned Subsidiary, Scilex Pharmaceuticals Inc., Entered into a Definitive Mutual Release and Settlement Agreement with Virpax Pharmaceuticals, Inc. Relating to the Previously Announced Term Sheet with Virpax in Respect of Such Release and Settlement	15/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Scilex Holding Company

Azioni

SCLX

US80880W1062

Altre lingue

Filtri